Gynecologic Oncology Articles

Promise on the Horizon in Advanced Endometrial Cancer
Alexandra Taylor, MD, discusses the advances with targeted therapies in endometrial cancer, as well as the challenges that still exist in the treatment and management of patients with advanced disease.
Involved Margins, High-Risk HPV Post-Treatment Predict Treatment Failure in Cervical Cancer
Results from a systemic review and meta-analysis of data collected from nearly 45,000 women treated for cervical precancer found that high-risk HPV posttreatment was a more accurate predictor of treatment failure than incomplete rescission.
IDO Plus PD-1 Inhibitor Combo Sparks Responses in Bladder and Cervical Cancers
The combination of nivolumab and BMS-986205 generated promising response rates without increasing adverse effects in patients with advanced cervical or bladder cancers.
Bevacizumab Biosimilar Nears European Approval
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of the bevacizumab biosimilar ABP 215 for the treatment of patients across several tumor types.
How Reliable Is PD-L1 Expression as a Predictor of Immune Response?
There is a great need—and opportunity—to improve ovarian cancer outcomes by understanding the immune milieu of ovarian cancers and harnessing the power of immunotherapy.
Endometrial Cancer Enters Immunotherapy Age
The tumor-site agnostic FDA approval of the PD-1 inhibitor pembrolizumab (Keytruda) for patients with microsatellite instability-high or mismatch repair deficient  solid tumors has helped propel endometrial cancer into the immunotherapy age.
Cisplatin Chemoradiation Proves Benefit in Stage IIIB Cervical Cancer
Umesh Mahantshetty, MD, shares his insight on the state of cervical cancer treatment in developing countries.
Tisotumab Vedotin Shows Clinical Benefit and Ongoing Responses in Cervical Cancer
A first-in-human study showed that the antibody drug conjugate tisotumab vedotin was well-tolerated and provided promising anti-tumor activity in patients with relapsed, recurrent, and/or metastatic cervical cancer. 
Pembrolizumab Demonstrates Safety and Efficacy in Cervical Cancer
In phase Ib results from the KEYNOTE-028 trial, pembrolizumab (Keytruda) was found to be active in cervical cancer while demonstrating safety results similar to previous studies with the PD-1 inhibitor.
FDA Accepts sBLA for Bevacizumab in First-Line Ovarian Cancer
The FDA has accepted a supplemental biologics license application for bevacizumab (Avastin) for the first-line treatment of advanced ovarian cancer.
Publication Bottom Border
Border Publication